schizophrenia
Conditions
Interventions
Qutiapine 400-750mg/d
Clozapine 200-600 mg/d
Perphenazine 20-60 mg/d
Sponsors
Sixth Hospital, Peking University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Male or female, 18-60 years old; 2. Chinese of Han descents; 3. with written informed consent for genetic study; 4. recruited from the outpatient and inpatient departments of psychiatric hospitals; 5. fulfilling the DSM-IV criteria for schizophrenia; 6. The total score of the PANSS of patients were above 60 when they are enrolled in the study.
Exclusion criteria
Exclusion criteria: The patients will be excluded when they: 1. be diagnosed as the mental retardation, alcohol or drug addiction, according to the DSM-IV; 2. suffered from the severe physical diseases, such as diabetes mellitus, thyroid gland disease, hypertension, other diseases as angel-closure glaucoma, epilapsy (febrile convulsion could be included); 3. ever received the sustained-release antipsychotics, ECT or clozapine therapy one month ago; 4. ever suffered from severe side effects related to antipsychotics, such as NMS, EPS, TD; 5. with severe suicidal ideas or obvious excitation and agitation; 6. with obvious abnormal index of laboratory examination; 7. with poor therapeutic compliance or without custodians; 8. with QTc interphase longer than 470 mses; 9. female in pregnancy or lactation periods or planning to pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive and negative symptom scale (PANSS); | — |
Countries
China
Contacts
Public ContactZHang Dai
Outcome results
None listed